The Global Health Body Issues Alert Over Acute Scarcity of Weight-Loss Jabs

Under a tenth of people that would benefit from obesity jabs including Wegovy can access them, caution the World Health Organization as it releases its first advice on the medications.

With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just availability to these injectable treatments.

Per projections, more than two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidelines acknowledges that excess weight is a lifelong illness that can be treated with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are major barriers to universal access to the injections that can aid individuals in losing substantial weight, says the agency.

Skinny Jab Shortage

Even in the current most favorable case, the manufacturing of these medications would only suffice for approximately 100 million people – fewer than 10% of the global need, per the WHO.

The recommendation urges governments and firms to widen access, via approaches including voluntary licensing.

The intellectual property rights on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.

The Way Obesity Jabs Operate

These medications mimick a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals reduce food intake.

Individuals typically see weight reduction after several weeks of starting on the once-weekly jabs.

Studies indicates users may regain a significant portion within a year of discontinuing the drug, because their typical appetite resume.

To be above a healthy weight increases your risk for developing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Excess weight impacts people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.